Results 141 to 150 of about 20,060 (180)
Some of the next articles are maybe not open access.
Emerging strategies for pegylated interferon combination therapy
Nature Clinical Practice Gastroenterology & Hepatology, 2007Several advances afford promise for improving the management of hepatitis C virus (HCV) infection. Current therapies primarily target the immune system; the now proven ability to culture the entire virus in vitro could ultimately facilitate the identification of therapies directly targeting viral replication.
openaire +2 more sources
Treatment with Interferons (including Pegylated Interferons) in Patients with Hepatitis B
Seminars in Liver Disease, 2004Studies of 4 to 6 months of treatment with interferon for hepatitis B e antigen (HBeAg)-positive chronic hepatitis B virus (HBV) infection have shown clearance of HBeAg to be higher in treated patients than it is in controls by approximately 25%. These results are considerably better than those with antiviral agents.
openaire +2 more sources
Pegylated interferons: chemical and clinical differences
Alimentary Pharmacology & Therapeutics, 2004SummaryPegylated interferon therapy for the treatment of chronic hepatitis C virus provides significant increases in sustained virological response rates compared with standard interferons. Two pegylated interferons are now available and are used in conjunction with ribavirin to maximize response rates in infected patients.
openaire +1 more source
Pegylated interferon-α2a versus pegylated interferon-α2b in hepatitis C
European Journal of Gastroenterology & Hepatology, 2014Andrea, Messori +4 more
openaire +2 more sources